OR WAIT null SECS
September 18, 2018
The $425-million acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.
September 02, 2018
Existing software tools cannot take into account the complexity of disease.
August 01, 2018
Determining how much containment is needed for API handling requires evaluation of multiple factors.
This article provides a sampling of the latest investments, expansions, and acquisitions by small-molecule contract service providers.
Heightened uncertainty means CDMO executives need to play out planning scenarios.
A year’s worth of FDA warning letters suggest that API and finished drug manufacturers should strengthen their approach to continued process verification.
July 24, 2018
The glass and chemical provider will expand its synthetic pharmaceutical intermediate and API production capacity at its plant in Chiba, Japan.
July 23, 2018
The acquisition will place Cambrex into the finished dosage form CDMO market.
July 18, 2018
CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.
June 25, 2018
Minakem’s facility in Belgium enhances capacity to scale production of highly potent ingredients for small to full GMP batches.